metformin has been researched along with Granulocytic Leukemia, Chronic in 8 studies
Metformin: A biguanide hypoglycemic agent used in the treatment of non-insulin-dependent diabetes mellitus not responding to dietary modification. Metformin improves glycemic control by improving insulin sensitivity and decreasing intestinal absorption of glucose. (From Martindale, The Extra Pharmacopoeia, 30th ed, p289)
metformin : A member of the class of guanidines that is biguanide the carrying two methyl substituents at position 1.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Phenformin's recently demonstrated efficacy in melanoma and Gleevec's demonstrated anti-proliferative action in chronic myeloid leukemia may lie within these drugs' significant pharmacokinetics, pharmacodynamics and structural homologies, which are reviewed herein." | 8.95 | Structural homologies between phenformin, lipitor and gleevec aim the same metabolic oncotarget in leukemia and melanoma. ( Boros, LG; Collins, TQ; D'Agostino, DP; Hitendra, P; Meuillet, EJ; Somlyai, G, 2017) |
| "Phenformin's recently demonstrated efficacy in melanoma and Gleevec's demonstrated anti-proliferative action in chronic myeloid leukemia may lie within these drugs' significant pharmacokinetics, pharmacodynamics and structural homologies, which are reviewed herein." | 4.95 | Structural homologies between phenformin, lipitor and gleevec aim the same metabolic oncotarget in leukemia and melanoma. ( Boros, LG; Collins, TQ; D'Agostino, DP; Hitendra, P; Meuillet, EJ; Somlyai, G, 2017) |
| " Of the over 325 members of the solute carrier superfamily, this review focuses on the molecular features, expressional regulation, and genetic polymorphisms of the organic cation transporter (OCT) family, and the pharmacokinetic or pharmacodynamic consequences for organic cationic drugs." | 2.44 | Organic cation transporters and their pharmacokinetic and pharmacodynamic consequences. ( Choi, MK; Song, IS, 2008) |
| "Metformin is a widely prescribed glucose-lowering agent for patients with diabetes and in preclinical studies, has been shown to suppress cell viability, induce apoptosis, and downregulate the mTORC1 signaling pathway in imatinib resistant CML cell lines (K562R)." | 1.72 | Impact of metformin on tyrosine kinase inhibitor response in chronic myeloid leukemia. ( Gilreath, JA; Pokorny, R; Stenehjem, DD, 2022) |
| "Metformin is a front-line drug for the treatment of type 2 diabetes, and several studies have shown that diabetes patients treated with metformin have reduced incidence of cancer." | 1.62 | Metformin enhances the cytotoxic effect of nilotinib and overcomes nilotinib resistance in chronic myeloid leukemia cells. ( Choi, CW; Kim, DS; Lee, DH; Na, YJ; Oh, SC; Yu, ES, 2021) |
| "Metformin was not a substrate of P-gp but suppressed the elevated level of P-gp in K562/Dox cells." | 1.43 | Targeting P-glycoprotein expression and cancer cell energy metabolism: combination of metformin and 2-deoxyglucose reverses the multidrug resistance of K562/Dox cells to doxorubicin. ( Huo, X; Liu, K; Liu, Q; Liu, Z; Ma, X; Meng, Q; Peng, J; Sun, H; Wang, C; Xue, C, 2016) |
| "Five patients with type 2 diabetes, three of them treated with insulin and two with oral antidiabetic drugs, receiving imatinib due to chronic myeolid leukaemia are reported." | 1.34 | [No influence of imatinib on type 2 diabetes]. ( Chodorowski, Z; Hellmann, A; Prejzner, W; Sein Anand, J, 2007) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (25.00) | 29.6817 |
| 2010's | 3 (37.50) | 24.3611 |
| 2020's | 3 (37.50) | 2.80 |
| Authors | Studies |
|---|---|
| Pokorny, R | 1 |
| Stenehjem, DD | 1 |
| Gilreath, JA | 1 |
| Gayatri, MB | 1 |
| Kancha, RK | 1 |
| Patchva, D | 1 |
| Velugonda, N | 1 |
| Gundeti, S | 1 |
| Reddy, ABM | 1 |
| Na, YJ | 1 |
| Yu, ES | 1 |
| Kim, DS | 1 |
| Lee, DH | 1 |
| Oh, SC | 1 |
| Choi, CW | 1 |
| Somlyai, G | 1 |
| Collins, TQ | 1 |
| Meuillet, EJ | 1 |
| Hitendra, P | 1 |
| D'Agostino, DP | 1 |
| Boros, LG | 1 |
| Xue, C | 1 |
| Wang, C | 1 |
| Liu, Q | 1 |
| Meng, Q | 1 |
| Sun, H | 1 |
| Huo, X | 1 |
| Ma, X | 2 |
| Liu, Z | 1 |
| Peng, J | 1 |
| Liu, K | 1 |
| Choi, MK | 1 |
| Song, IS | 1 |
| Vakana, E | 1 |
| Altman, JK | 1 |
| Glaser, H | 1 |
| Donato, NJ | 1 |
| Platanias, LC | 1 |
| Chodorowski, Z | 1 |
| Sein Anand, J | 1 |
| Hellmann, A | 1 |
| Prejzner, W | 1 |
2 reviews available for metformin and Granulocytic Leukemia, Chronic
| Article | Year |
|---|---|
Structural homologies between phenformin, lipitor and gleevec aim the same metabolic oncotarget in leukemia and melanoma.
Topics: Atorvastatin; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Melanoma; | 2017 |
Organic cation transporters and their pharmacokinetic and pharmacodynamic consequences.
Topics: Animals; Benzamides; Cisplatin; Humans; Imatinib Mesylate; Kidney; Leukemia, Myelogenous, Chronic, B | 2008 |
6 other studies available for metformin and Granulocytic Leukemia, Chronic
| Article | Year |
|---|---|
Impact of metformin on tyrosine kinase inhibitor response in chronic myeloid leukemia.
Topics: Adult; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloi | 2022 |
Metformin exerts antileukemic effects by modulating lactate metabolism and overcomes imatinib resistance in chronic myelogenous leukemia.
Topics: Adenosine Triphosphate; Apoptosis; Cell Line, Tumor; Drug Resistance, Neoplasm; Glucose; Humans; Ima | 2023 |
Metformin enhances the cytotoxic effect of nilotinib and overcomes nilotinib resistance in chronic myeloid leukemia cells.
Topics: Antineoplastic Agents; Diabetes Mellitus, Type 2; Drug Resistance, Neoplasm; Humans; Leukemia, Myelo | 2021 |
Targeting P-glycoprotein expression and cancer cell energy metabolism: combination of metformin and 2-deoxyglucose reverses the multidrug resistance of K562/Dox cells to doxorubicin.
Topics: Antibiotics, Antineoplastic; Antimetabolites; Apoptosis; ATP Binding Cassette Transporter, Subfamily | 2016 |
Antileukemic effects of AMPK activators on BCR-ABL-expressing cells.
Topics: Amino Acid Substitution; Aminoimidazole Carboxamide; AMP-Activated Protein Kinase Kinases; Antineopl | 2011 |
[No influence of imatinib on type 2 diabetes].
Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Blood Glucose; Diabetes Complications; Diabetes Mell | 2007 |